Home > Oncology > ASCO GU 2022 > Prostate Cancer > Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity

Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity

Presented By
Dr Xin Gao, Massachusetts General Hospital, MA, USA
Conference
ASCO GU 2022
Trial
Phase 2, ARDENT
In the phase 2 ARDENT trial, the first-in-class, oral, PROteolysis TArgeting Chimera (PROTAC) protein degrader bavdegalutamide induced a clinically relevant PSA decline in patients with pre-treated metastatic castration-resistant prostate cancer (mCRPC). Bavdegalutamide (a.k.a. ARV-110) is an oral PROTAC protein degrader that selectively targets wildtype androgen receptor (AR) and clinically relevant mutants. Previous phase 1 data indicated clinical activity for bavdegalutamide in heavily pre-treated patients with mCRPC and suggested enhanced activity in patients with specific molecular profiles, like AR T878 and H875 mutations. This led to a phase 2 expansion to further characterise bavdegalutamide in biomarker-defined patient subgroups. The phase 2 expansion trial ARDENT (NCT03888612) enrolled patients with confirmed mCRPC who experienced disease progress...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on